TY - JOUR
T1 - Clinically Significant Enhancement of Voriconazole Efficacy by Moxifloxacin and Gentamicin in Fungal Keratitis
AU - Matoba, Alice Y.
AU - Divatia, Mukul K.
AU - Arguello, Robert A.
AU - Chévez-Barrios, Patricia
N1 - Funding Information:
Received for publication October 30, 2017; revision received January 5, 2018; accepted January 11, 2018. Published online ahead of print February 27, 2018. From the *Department of Ophthalmology, Baylor College of Medicine, Houston, TX; †The Methodist Hospital, Department of Pathology and Molecular Medicine, Houston, TX; and ‡McAllen, TX. Supported by an unrestricted grant from the Research to Prevent Blindness Foundation, New York, NY. The authors have no conflicts of interest to disclose. A. Y. Matoba: Writing of manuscript, analysis of clinical information, clinical management of patients; M. K. Divatia: Histopathological analysis, writing of manuscript; R. A. Arguello: Clinical management of patient, analysis of clinical information; P. Chevez-Barrios: Histopathological analysis, clinicopathological correlation. Correspondence: Alice Y. Matoba, MD, Alkek Eye Center, 1977 Butler Boulevard, E3.210, Houston, TX 77030 (e-mail: [email protected]). Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Publisher Copyright:
© 2018 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Purpose: To report the effect of topical antibiotics moxifloxacin 0.3% and gentamicin 0.3% on the clinical efficacy of topical antifungal agent voriconazole 1% in cases of culture- or biopsy-proven fungal keratitis. Methods: Two cases of fungal keratitis in which the addition of topical moxifloxacin or moxifloxacin and gentamicin led to an improved clinical response to topical voriconazole were reviewed retrospectively. Results: One patient with clinical resistance of his fungal keratitis to both topical voriconazole and natamycin had resolution of his keratitis with the addition of topical moxifloxacin and gentamicin to voriconazole. One patient who had a poor response to topical voriconazole had a dramatic response to the increase of the voriconazole regimen and addition of moxifloxacin. Conclusions: In a subset of patients with fungal keratitis, the addition of topical moxifloxacin 0.3% or moxifloxacin 0.3% and gentamicin 0.3% may enhance the therapeutic effect of topical voriconazole 1%.
AB - Purpose: To report the effect of topical antibiotics moxifloxacin 0.3% and gentamicin 0.3% on the clinical efficacy of topical antifungal agent voriconazole 1% in cases of culture- or biopsy-proven fungal keratitis. Methods: Two cases of fungal keratitis in which the addition of topical moxifloxacin or moxifloxacin and gentamicin led to an improved clinical response to topical voriconazole were reviewed retrospectively. Results: One patient with clinical resistance of his fungal keratitis to both topical voriconazole and natamycin had resolution of his keratitis with the addition of topical moxifloxacin and gentamicin to voriconazole. One patient who had a poor response to topical voriconazole had a dramatic response to the increase of the voriconazole regimen and addition of moxifloxacin. Conclusions: In a subset of patients with fungal keratitis, the addition of topical moxifloxacin 0.3% or moxifloxacin 0.3% and gentamicin 0.3% may enhance the therapeutic effect of topical voriconazole 1%.
KW - fungal keratitis
KW - gentamicin
KW - moxifloxacin
KW - voriconazole
UR - http://www.scopus.com/inward/record.url?scp=85047351135&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047351135&partnerID=8YFLogxK
U2 - 10.1097/ICO.0000000000001545
DO - 10.1097/ICO.0000000000001545
M3 - Article
C2 - 29489515
AN - SCOPUS:85047351135
SN - 0277-3740
VL - 37
SP - 651
JO - Cornea
JF - Cornea
IS - 5
ER -